logo

Canadian News

Share SHARE

The Australian dollar strengthened against the other major currencies in the Asian session on Monday. The Australian dollar rose to 86.87 against the yen, from Friday's closing value of 86.57. Against the euro, the aussie advanced to 1.3821 from an early low of 1.3864. This may be compared to...

Canadian stocks nudged lower Friday, ending an eight-day win streak that led to record highs for Toronto's main index. With financials taking a breather after a significant uptrend, the S&P/TSX Composite Index was down 25.54 points, or 0.16 percent, to 15,838.63. Gold shares struggled throughout...

Crude oil futures fell Friday, staying smack dab in the middle of a stubborn trading range amid further signs that U.S. production is spiking. Data from Baker Hughes Friday revealed that the number of active U.S. rigs drilling for oil rose by 6 to 597 rigs this week, for the fifth weekly increase...

The Canadian stock market got off to a weak start Friday, but has since pared its early losses. However, the bulk of the Canadian sectors remain in the red this morning, including the energy, gold and financial sectors. Telecom and IT stocks are among the best performers in early trade. The majority...

Saputo-Recall-021717.jpg Dairy giant Saputo Inc. is voluntarily recalling certain Gouda cheese products in the U.S. due to potential listeria contamination. Saputo said one of its suppliers, Deutsch Kase Haus, LLC of Middlebury, Indiana, notified the company that some specialty Gouda cheese products that it supplied to Saputo's Green Bay, Wisconsin facility may have been contaminated with Listeria monocytogenes.

Canadian stocks look to end an historic week on a subdued note Friday, as traders may grow cautious after a run to all-time highs on both sides of the border. Toronto's main index jumped this week along with the U.S. DJIA, S&P and Nasdaq to fresh record highs, powered by gains among financials. Canadian...

Pulsebioscience-021717.jpg Shares of development-stage medical technology company Pulse Biosciences Inc. (PLSE) have gained nearly 30% so far this week.

Feb16-021617.jpg Neuralstem Inc.'s phase 2 trial of NSI-189 for the treatment of major depressive disorder has been completed ahead of schedule.

The Australian dollar strengthened against the other major currencies in the Asian session on Friday. The Australian dollar rose to nearly a 4-month high of 1.0708 against the NZ dollar, from yesterday's closing value of 1.0662. The aussie advanced to 0.7713 against the U.S. dollar, from an early...

The Japanese yen rose slightly against the other major currencies in the Asian session on Friday. The yen rose to 120.90 against the euro and 113.59 against the Swiss franc, from early lows of 121.09 and 113.78, respectively. Against the pound, the yen advanced to 141.59 from an early low of...

Fluor Corp. (FLR), an engineering, procurement, fabrication, construction and maintenance company, announced late Thursday that it has signed an agreement for Woodfibre LNG Project in Canada. Fluor booked the undisclosed contract value in the fourth quarter of 2016. The company signed the deal with...

Canadian stocks extended record highs with an eighth straight daily advance. The S&P/TSX Composite Index was up 19.22 points, or 0.12 percent, to 15,864.17 Thursday.. In corporate news, Bombardier (BBD.B.TO) narrowed its quarterly loss, but fell short of estimates on revenue. Management cited...

The Canadian stock market is up slightly Thursday morning in lackluster trading. Gold stocks are among the best performing stocks in early trade, despite speculation that the Fed is likely to hike interest rates sooner than had been expected. Meanwhile, healthcare stocks are turning in a weak performance...

Canadian stocks put a seven-day win streak on the line Thursday, and early signals are pointing to another positive start on Bay Street. Markets on both sides of the border have raced higher in February, driving the major indices to record highs. Financials have rallied on speculation the Trump...

pharma-021617.jpg Ardelyx Inc.'s (ARDX) phase III clinical trial of Tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis has met its primary endpoint and was generally well-tolerated.

Follow RTT